ARCHIVES

Gleevec Improves Survival Of CML In Accelerated Phase

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Researchers Take “Director’s Challenge” to Develop Molecular Profiles of Tumors

December 10, 1999

Conversation with The Cancer Letter: Is Republican Control Better Than Two-Party Stalemate?

December 19, 2014

Georgetown Names Cullen Interim Center Director.

November 3, 2000

NCI’s Share Of Gramm-Rudman Cuts For FY 1986 Is $54 Million; Staff Ponders How To Absorb It

January 24, 1986

New Safety Concerns On ESAs Prompt FDA To Consult ODAC Again.

January 11, 2008

FDA Approves Herceptin For HER2+ Metastatic Stomach Cancers

October 22, 2010